The low prevalence of anti‐IFN‐β NAB in COVID‐19 patients might have pathological consequences since there are differences between IFN‐α and ‐β in IFN receptor binding affinity and biological activities [21, 22]. This evidence concerns the gene IFNA2 and COVID-19.